Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.77), $0.36 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $201.5 million versus the consensus estimate of $198.61 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• MotorK names Roy Toren to board as Helen Protopapas resigns
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM